Breaking: SCOTUS says inventors can challenge their patents, but imposes limits

The US Supreme Court has upheld the doctrine of assignor estoppel in a dispute between Minerva and Hologic but has narrowed its scope. SCOTUS handed down the decision today, June 29, in a fractured 5-4 opinion that effectively bars an inventor from challenging their own patents, and imposing new limits when the principle of assignor estoppel can be invoked.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

SCOTUS asks for SG’s view on enablement in antibody dispute

19 April 2022 The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.

Big Pharma

Supreme Court hears Minerva v Hologic arguments

22 April 2021 The US Supreme Court heard oral arguments in Minerva Surgical v Hologic yesterday to discuss the potential abandoning of assignor estoppel.

Big Pharma

The importance of Minerva Surgical v Hologic

2 February 2021 A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.

More on this story

Americas

SCOTUS asks for SG’s view on enablement in antibody dispute

Big Pharma

Supreme Court hears Minerva v Hologic arguments

22 April 2021 The US Supreme Court heard oral arguments in Minerva Surgical v Hologic yesterday to discuss the potential abandoning of assignor estoppel.

Big Pharma

The importance of Minerva Surgical v Hologic

More on this story

Americas

SCOTUS asks for SG’s view on enablement in antibody dispute

Big Pharma

Supreme Court hears Minerva v Hologic arguments

22 April 2021 The US Supreme Court heard oral arguments in Minerva Surgical v Hologic yesterday to discuss the potential abandoning of assignor estoppel.

Big Pharma

The importance of Minerva Surgical v Hologic